


SMART IRB & Reliance Processes

Dr. Julie Doherty DM,MSN,RN,CIP,CCEP
Assistant Vice President, Research Compliance
Office of Accountability & Compliance
November 17, 2022



HUMAN RESEARCH PROTECTIONS PROGRAM



Reliance Mandates

NIH -Single IRB for Multi-Site Research

- Compliance date: January 25, 2018

 Revised Common Rule 45 CFR 46 - Single IRB for Cooperative Research

Compliance date: January 20, 2020

Common Rule 45 CFR 46 - Single IRB for Cooperative Research

- (a) Cooperative research projects are those projects covered by this policy that involve more than one institution.
- (b)(1) Any institution located in the United States that is engaged in cooperative research must rely upon approval by a single IRB for that portion of the research that is conducted in the United States.

The reviewing IRB will be identified by the Federal department or agency supporting or conducting the research or proposed by the lead institution subject to the acceptance of the Federal department or agency supporting the research.

sIRB -Common Rule

- The following research is not subject to this provision:
 - (i) Cooperative research for which more than single IRB review is required by law (including tribal law passed by the official governing body of an American Indian or Alaska Native tribe); or

sIRB - Common Rule

- Research for which any Federal department or agency supporting or conducting the research determines and documents that the use of a single IRB is not appropriate for the particular context.
- (c) For research not subject to paragraph (b) of this section, an institution participating in a cooperative project may enter into a joint review arrangement, rely on the review of another IRB, or make similar arrangements for avoiding duplication of effort.

sIRB Common Rule

• Exceptions:

Research approved prior to January 2020

Common Rule Agencies

- Department of Agriculture
- Department of Energy
- NASA
- Department of Commerce
- Agency for International Development
- Department of Defense
- Department of Education
- Department of Homeland Security
- Department of Veterans Affairs
- Department of Labor

Common Rule Agencies

- Environmental Protection Agency
- Department of Health and Human Services
- National Science Foundation
- Department of Transportation
- Office of the Director of National Intelligence
- Central Intelligence Agency
- Consumer Product Safety Commission
- Social Security Administration

sIRB - NIH

- The National Institutes of Health (NIH) issued this policy on the use of a single Institutional Review Board (IRB) for multi-site research
- Establish the expectation that a single IRB (sIRB)
 of record will be used in the ethical review of non exempt human subjects research protocols funded
 by the NIH that are carried out at more than one
 site in the United States.

sIRB NIH

Goal

- Enhance and streamline the IRB review process in the context of multi-site research
- Research can proceed as effectively and expeditiously as possible.

sIRB -NIH

- Eliminating duplicative IRB review is expected to reduce unnecessary administrative burdens and systemic inefficiencies without diminishing human subjects protections.
- The shift in workload away from conducting redundant reviews is also expected to allow IRBs to concentrate more time and attention on the review of single site protocols, thereby enhancing research oversight.

Food and Drug Administration

- The Food and Drug Administration (FDA) is an HHS agency that regulates clinical investigations of products under its jurisdiction, such as drugs, biological products, and medical devices.
- FDA is not considered a Common Rule agency because its regulations differ from the Common Rule. However, FDA is required to harmonize with the Common Rule whenever permitted by law (see section 1002 of the 21st Century Cures Act, Public Law 114-255)

Food and Drug Administration

 On September 28, 2022, the U.S. Food and Drug Administration ("FDA") issued two Notices of Proposed Rule Making to harmonize FDA's regulations pertaining to human subjects research and the review of cooperative research by a single institutional review board with those of the Federal Policy for the Protection of Human Subjects.

Stay tuned.....

Processes

- * Reliance on an external IRB
 - Multi-site/cooperative
 - CICERO -Truncated application
 - Regardless of funding
- * UMB is IRB of record
 - Multi-site/cooperative
 - CICERO –Full application
 - Regardless of funding

Reliance Processes


- CICERO
 - Departmental review
 - Ancillary reviews
 - Conflict of interest
 - Radiation Safety (RSC)
 - Institutional Biosafety (IBC)
 - Investigational Drug Service
 - GCRC (as applicable)

Reliance

- Platform designed to ease common challenges associated with initiating multisite research and to provide a roadmap for institutions to implement the <u>NIH Single IRB Review policy</u> (effective date: January 25, 2018).
- https://smartirb.org/
- Provides an easy way for investigators and institutions to track and document reliance arrangements on a study-by-study basis.

- Streamlined, Multisite, Accelerated Resources for Trials IRB Reliance platform
- Designed to harmonize and streamline the IRB review process for multisite studies, while ensuring a high level of protection for research participants.

 Freely available for institutions and investigators, SMART IRB is an integrated, comprehensive platform that allows flexibility in the size and scope of collaboration to enable IRB reliance for multisite studies across the nation, regardless of funding status.



- Is not an IRB
- Rather, it's a platform that offers a master IRB reliance agreement (the SMART IRB Agreement) and a web-based system (SMART IRB's Online Reliance System)
- Provides a central process for participating institutions and their investigators to request, track, and document study-specific reliance arrangements.

- Master Common Reciprocal Institutional Review Board Authorization Agreement
- Institutional Profile
- 1042 participating institutions
 - CTSA hubs and affiliates, universities, academic medical centers, community hospitals, cancer centers, independent IRB organizations

Master Reciprocal Agreement

Reliance requests

Institutional official

Reviewed individually

Approved/acknowledged on a case-by-case basis



RESOURCES

RELIANCE PROCESSES

Consult with the UMB Human Research
 Protections Office prior to grant submissions
 and IRB submissions

Reliance on external IRB

Grant letter of support


Getting Started


Required Trainings:

- Collaborative Institutional Training Initiative (CITI)
 - www.citiprogram.org
 - Course in the Protection of Human Subjects
 - Good Clinical Practices (NIH)
 - Affiliate with University of Maryland, Baltimore or Baltimore, MD-512 (VA)
 - Note: CICERO account and CITI account are not linked!
- HIPAA 125: Privacy and Security Review
- HIPAA 201: Human Research

Reliance Processes

- Simultaneously
 - Submit in CICERO
 - Submit in SMART IRB
 - Collaborate with other study sites
 - Roles differ based on who is IRB of record





Ask questions!

- IRB Reliance Analyst Scott Evans
 - sevans@umaryland.edu
- IRB Manager Jan Martinez
 - Jan.Martinez@umaryland.edu
- Assistant Vice President, Research Compliance
 - Julie Doherty jdoherty@umaryland.edu
- Contact information is available at http://www.umaryland.edu/hrp/hrp-office/hrpo-personnel/

Questions?

Human Research Protections

Office of Accountability & Compliance

620 W. Lexington Street, 2nd Floor

410-706-5037

hrpo@umaryland.edu

www.umaryland.edu/hrp

UMB HRPO External IRB Analyst: Scott Evans 410-706-3893 sevans@umaryland.edu

UMMC Human Protections Administrator: Joanne Marshall 410-908-6272 Joanne.marshall@umm.edu